Kornimate/medical-research-clean huggingface dataset:
resistance training in cardiovascular disease patients

Conditions: Coronary Artery Disease; Heart Failure With Reduced Ejection Fraction

Summary: in this study coronary artery disease patients and patients with heart failure will be randomly assigned to three training groups: combined aerobic interval training with high intensity resistance training, combined aerobic interval training with low intensity resistance training and aerobic interval training.

exercise-based cardiac rehabilitation programmes have predominantly used aerobic-dynamic exercise modalities, whereas resistance training have been discouraged in patients with cardiovascular disease, due to safety concerns related to cardiovascular response (heart rate and blood pressure) during the exertion. contrary to such concerns, recent hemodynamic studies have reported lower blood pressure and heart rate during higher intensity resistance training (\>70 % 1-rm) compared to lower intensity resistance training (\>40 % 1-rm). furthermore, the latest meta analysis have demonstrated that combined resistance training with standard aerobic interval training has been superior than aerobic training alone in several aspects of health. however, there is still huge heterogeneity in training intervention design, also there still lacks studies to further elucidate the effects of high intensity resistance training combined with aerobic training on physical performance (aerobic capacity, muscle strength, balance), body composition, quality of life, morbidity, mortality, etc. therefore, the aim of this study was to examine the effects of high (70%-80 % 1-rm) versus low loads (30%- 40 % 1-rm) resistance training in combination with aerobic interval cycling (50 % -80% of baseline peak power output) in coronary artery disease patients and patients with heart failure.

Eligibility criteria:
inclusion criteria: * stable patients with documented cad with clinical event (\>1 month after acute coronary syndrome and/or percutaneous coronary intervention) or coronarography and/or * stable heart failure patients with documented reduced ejection fraction (\>40-45 %) * age \>18 years * nyha class i-iii * cardiopulmonary exercise test without ecg abnormalities exclusion criteria: * unstable chd * decompensated hf * uncontrolled arrhythmias * severe and symptomatic aortic stenosis * acute myocarditis, endocarditis, or pericarditis * aortic dissection * marfan syndrome * musculoskeletal limitations

Keywords: resistance training coronary artery disease heart failure hemodynamic response cardiac rehabilitation aerobic training
efficacy and safety of pulsed field ablation in refractory mitral isthmus-dependent atrial flutter: pulsed field ablation vs. radiofrequency ablation: a preliminary randomized controlled study

Conditions: Atrial Fibrillation (AF)

Summary: efficacy and safety of pulsed field ablation in refractory mitral isthmus-dependent atrial flutter: pulsed field ablation vs. radiofrequency ablation: a preliminary randomized controlled study

this study aims to compare the effectiveness of pulse field ablation (pfa) versus radiofrequency ablation (rfca) in improving mitral valve commissural block rate and atrial tachycardia recurrence rate in patients with refractory mitral valve commissural-dependent atrial flutter. study design: randomized groups: patients will be randomly assigned to two groups: pulse field ablation (pfa) group radiofrequency ablation (rfca) group

Eligibility criteria:
inclusion criteria: 1.patients aged ≥18 years. 2.diagnosed with persistent symptomatic refractory mitral valve commissural-dependent atrial flutter. refractory mitral valve commissural-dependent atrial tachycardia is defined as: 1. failure of drug therapy: at least one class i or iii antiarrhythmic drug (e.g., propafenone, amiodarone) fails to effectively control or prevent episodes. 2. failure of catheter ablation: at least one previous attempt at radiofrequency catheter ablation (rfca) targeting the mitral valve commissure has been unsuccessful (either due to recurrence post-procedure or failure to achieve bidirectional block at the commissure). 3.intolerant to at least one antiarrhythmic drug (aad). 4.the patient must be capable of and willing to provide written informed consent to participate in this study. exclusion criteria: 1. pregnant or breastfeeding women. 2. presence of left atrial thrombus on preoperative imaging. 3. life expectancy less than 1 year. 4. coagulation disorders or contraindications to anticoagulant therapy.

Keywords: mitral isthmus pfa
probiotics for girls with recurring urinary tract infections

Conditions: Recurrent Urinary Tract Infection

Summary: probiotics are dietary supplements containing potentially beneficial bacterial strains such as lactobacillus. the safety of oral administration of probiotics has been demonstrated in hundreds of studies using adults over the last 30 years. very few studies have been conducted with children. uti in girls occur when virulent bacteria migrate from the rectum and colonize the vagina and peri-urethral mucosa, thus gaining access to the bladder. this study will randomize girls to arm a (probiotics + placebo) and arm b (antibiotics + placebo) to determine if utis are decreased when the probiotics are given.


Eligibility criteria:
inclusion criteria: * girls age 1 through age 17 years of age * must have had at least 3 symptomatic uti, uncomplicated or complicated, in the year preceding study inclusion or already using any form of prophylaxis to prevent recurrences of uti * must have had at least 3 symptomatic urinary tract infections in the year before the start of the prophylaxis. exclusion criteria: * breastfeeding * pregnancy * prior adverse reaction to sulfa drugs or sulfamethoxazole/trimethoprim * known immunosuppression i.e., transplant recipients or children with congenital immunodeficiencies * poorly controlled diabetes * untreated hiv infection * use of high dose corticosteroids for autoimmune diseases or post-organ transplantation. inhaled corticosteroids or oral steroids for asthma are allowed. * malnutrition * patients with a history of sulfamethoxazole/trimethoprim-resistant uti will be excluded from the study * patients with renal insufficiency, liver insufficiency, or cardiopulmonary disease requiring medication will be excluded from the study * patients with known anemia will be excluded from the study * patients taking medications that may interact with sulfamethoxazole/trimethoprim will be excluded from the study * patients taking other probiotics will be excluded from the study * patients already taking prophylactic antibiotics will be excluded from the study

Keywords: urinary tract infection probiotics dietary supplements bacteriuria
reflexo therapy for gestational diabetes mellitus

Conditions: Physical Therapy

Summary: the purpose of this study will be to detect the effects of reflexo therapy of sole on gdm.

gestational diabetes mellitus is considered a hazard factor for antenatal complications for both mother and fetus. it is characterized by glucose intolerance of variable degrees with the beginning or first recognition of pregnancy. it affects 14% of pregnancies worldwide, and it undergoes continuous changes in the diagnostic criteria, ethnicity and the population studied. there is an increasing prevalence of diabetes mellitus, and its major metabolic disorder caused by the insulin secretion defect or insulin action defect resulting from a defect in insulin secretion, insulin action, or both. as a result, it will lead to chronic hyperglycemia associated with carbohydrates, protein, and fat disturbance. in spite of the fact that the reason for gestational diabetes mellitus is still not fully understood, it is proposed that human placental lactogen has growth hormone-like actions, and that it causes lipolysis and thus increases the levels of circulating fatty acids that repress the action of insulin and cause insulin resistance in pregnant females which appear to play a crucial role in the pathogenesis of gestational diabetes mellitus.

Eligibility criteria:
inclusion criteria: 1. they were maternally aged between 20 and 35 years. 2. the gestational age ranged from between 24 and 36 weeks. 3. their bmi didn't exceed 30 kg/m2. 4. a singleton live fetus and not under stressful event. exclusion criteria 1. they had high-risk pregnancies. 2. bad obstetric situations. 3. diseases that could interfere with participation. 4. smoking. 5. oral sedative administration.

Keywords: gestational diabetes mellitus foot reflexology fasting plasma glucose 2-h post-prandial glucose hba1c
a phase 2 study of efficacy and safety of ak111 in subjects with moderate-to-severe psoriasis

Conditions: Psoriasis

Summary: this is a randomized, double-blind, placebo-controlled, multi-center phase ii clinical study to evaluate the efficacy and safety of ak111 for the treatment of moderate to severe plaque psoriasis.

this is a randomized, double-blind, placebo-controlled, multi-center phase ii clinical study to evaluate the efficacy and safety of ak111 in subjects with moderate to severe plaque psoriasis. the study will consist of 4 periods: up to 4 weeks screening period, 12 weeks placebo-controlled period,12 weeks crossover treatment period,44 weeks long-term treatment period.

Eligibility criteria:
key inclusion criteria: 1. male or female, 18 to 75 years of age 2. moderate to severe plaque-type psoriasis diagnosed for at least 6 months 3. moderate-to-severe plaque psoriasis as defined at baseline by meeting all three criteria: 1. clinical diagnosis of stable plaque psoriasis with involvement of ≥ 10% body surface area. 2. psoriasis area and severity index(pasi) ≥12. 3. static physicians global assessment score ≥3. 4. subjects with a history of an inadequate response, intolerable or medically inappropriate use of systemic therapy and/or phototherapy. 5. subjects who are women of childbearing potential must have a negative urine pregnancy test at screening and must be practicing an adequate, medically acceptable method of birth control for at least 8 months after the last study drug administration. key exclusion criteria: 1. forms of psoriasis other than chronic plaque-type psoriasis. 2. history or evidence of active tb, patients with evidence of latent tuberculosis may enter the trial after sufficient treatment according to protocol. 3. positive results of confirmatory serology test for hepatitis b, hepatitis c, hiv or syphilis at screening. 4. history of a serious or systemic infection within 2 months before screening. 5. history of malignancy of any organ system within the past 5 years. 6. inadequate washout period for prior drug therapy. 7. previous use of secukinumab, ixekizumab or any other drug that targets il-17 or il-17 receptor. 8. any medical conditions, in the opinion of the investigator or the sponsor's medical monitor, would place the subject at risk, interfere with study participation or study results interpretation.

Keywords: ak111 efficacy safety
the effect of bariatric/metabolic surgery on gfr

Conditions: Metabolic Syndrome

Summary: the purpose of this study is to determine the change in kidney function and blood pressure after gastric bypass versus conventional medical therapy in morbid obesity. the study mainly focus on glomerular filtration rate(gfr) with known relation to the renal function and 24 hours ambulatory blood pressure monitoring after intervention of gastric bypass or medical treatment.

metabolic syndrome is strongly associated with obesity and the patients with this syndrome are at increased risk for cardiovascular disease. obesity constitutes a strong risk factor for the development of chronic kidney disease. among diabetics, obesity is known to amplify the risk for kidney disease. bariatric surgery has yielded dramatic results including longitudinal loss of excess body weight and either complete reversal or significant improvement of several features of metabolic syndrome. in addition, many observational studies have demonstrated significant reduction in proteinuria after bariatric surgery. however, the changes in the component of cardiovascular problem among metabolic syndrome and changes in renal filtration function or progression to end stage kidney disease in morbidly obese patients after weight loss surgery have not been extensively studied. therefore, our study mainly focus on glomerular filtration rate(gfr) with known relation to the renal function and 24 hours ambulatory blood pressure monitoring after intervention of gastric bypass or medical treatment.

Eligibility criteria:
inclusion criteria: * morbid obesity (bmi\>30) patients with one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) * morbid obese patients (bmi\>35) exclusion criteria: * prior bariatric surgery * malignancy (any type) * end stage renal disease
evaluation of patients with endocrine-related conditions

Conditions: Adrenal Insufficiency; Pituitary Neoplasm; Obesity

Summary: this study will evaluate patients with a variety of endocrine disorders in order to 1) learn more about conditions that affect the endocrine glands (glands that secrete hormones) and 2) to train physicians in endocrinology. patients of all ages with endocrine-related conditions may be eligible for evaluation under this protocol. those enrolled may be required to provide blood, saliva, urine or stool samples, and to undergo ultrasound examination of the thyroid gland, ovaries or testes, adrenal glands or other parts of the body. laboratory or x-ray studies may be done for diagnostic or treatment purposes. in some cases, patients will receive medical or surgical treatment for their disorder. patients and family members of patients with a hereditary disorder may be asked to provide a blood sample for genetic analysis.

this protocol is designed to allow inpatient and outpatient evaluation of adults with a variety of endocrine disorders for purposes of research and physician education in our accredited endocrinology training programs. the research-directed evaluations may include blood, saliva, or urine samples, or evaluation tissue that was routinely collected for clinical care. in some patients with endocrine disorders, laboratory or radiological studies will be performed to confirm a diagnosis or to aid in the management of the patient, using standard approaches in current clinical practice. in some cases, the patient will receive medical, radiation or surgical treatment for their disorder. the purpose of these evaluations or treatments to support our clinical training or research missions.

Eligibility criteria:
* inclusion criteria: * adult patients of all ages with endocrine-related conditions will be eligible for this protocol. * both male and female subjects of all ethnic backgrounds are eligible. exclusion criteria: * unstable patients and patients with severe organ failure that may affect/limit the endocrine work-up and exhaust clinical center and/or nichd resources will be excluded if appropriate. decisions will be made on a case by case basis by investigators. * subjects who are unable to provide informed consent will not be accrued; however, if patients have previously given consent, they will continue to be seen for ongoing clinical care. if they require medically-indicated procedures, we will follow nih policy regarding obtaining consent from next of kin if they have not indicated a medical decision maker. * minor subjects will not be accrued; they will be referred to nichd protocols or other niddk protocols for evaluation of eligibility. * prisoners will not be recruited. if a subject becomes incarcerated during the study, s/he may continue to participate so as to not compromise medical care.

Keywords: healthy volunteers endocrine related conditions endocrine dysfunction early pubertal development
anti-obesity pharmacotherapy and inflammation

Conditions: Obesity

Summary: this study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

this study aims to determine if weight loss by pharmacotherapy with liraglutide, semaglutide, or phentermine-topiramate promotes the reduction of pro-tumoral inflammatory cells myeloid-derived suppressor cells (mdsc), simultaneously to the improvement of lipid profile (ldl-cholesterol, hdl-cholesterol, triglycerides, and free fatty acids) and concentration in the blood. liraglutide, semaglutide, and phentermine-topiramate are fda-approved medications to treat obesity and obesity-associated comorbidities. twenty-four patients undergoing standard of care for anti-obesity treatment at va medical center, and tulane center for clinical research (tccr) will be recruited before initiation of pharmacotherapy as part of their standard of care and followed up to 6 months to compare the primary study variables.

Eligibility criteria:
inclusion criteria: * body mass index (bmi): over 30 kg/m2 * age: 35 to 60 years old exclusion criteria: * taking medications with anti-inflammatory properties like glucocorticoids, prednisone, or non-steroidal anti-inflammatory medications, such as aspirin or motrin subjects on medications for long-term weight management such as phentermine-topiramate (qsymia), orlistat (xenical), naltrexone-bupropion (contrave), and the glucagon-like peptide-1 receptor agonists such as liraglutide (saxenda), and semaglutide (wegovy). * prior history of cancer * having any clinical symptoms of systemic inflammation, acute infections such as coronavirus disease 2019, or chronic diseases such as cancer, tuberculosis, autoimmune disease, and aids * an adult unable to consent * prisoner * pregnancy or breastfeeding women

Keywords: inflammation dyslipidemia metabolic syndrome
electronic-nutrition-optimizer for personalized prevention

Conditions: Diabetes; Hypertension; Frailty; Dementia; Cardiovascular Diseases

Summary: this study aims to develop and validate a tool for immediate nutrition assessment and to test its user feasibility in routine clinical practice for health promotion.

small changes in diet have been shown to have an important impact on health and the risk of age-related chronic diseases, such as cardiovascular disease, diabetes, frailty and dementia. however, this knowledge has not yet been implemented into routine clinical practice, because practical tools that allow a comprehensive nutrition assessment in the clinical care setting are missing. in addition, doctors are generally not educated in giving nutritional advice to patients. in this pilot project, we aim to push forward and enable the potential of nutrition as a core primary prevention strategy for people at risk of developing chronic diseases. this will be achieved by using, as a stepping stone, the electronic 216-food-item food frequency questionnaire which was developed for the european do-health study and was tested in over 2000 adults. the investigators want to extend this tool to not only capture the personal dietary intake, but also to produce an immediate report, comparing the personal diet to the mediterranean and mind diet patterns and providing a patient's intake of protein and other nutrients. the report will additionally indicate the patient's diet-related, personalized risks of cardio-vascular disease, diabetes, frailty and cognitive decline, and recommend dietary changes to reduce these risks.

Eligibility criteria:
inclusion criteria: 1. stable inpatients from the department of heart surgery, or center for senior trauma patient at the university hospital zurich (inpatient group) 2. ambulatory volunteers who can visit the center for aging and mobility (cam) independently ("outpatients" group) 3. ≥50 years exclusion criteria: 1. if already involved in another ongoing interventional clinical trial, except an interaction with this intervention can be excluded 2. people with an impaired short-term memory (mmse \<24) 3. patients following a specific diet recommended by a medical professional, due to diseases such as diabetes, chronic diseases of the gastrointestinal tract, severe kidney disease, or patients allergic to the main components of the mediterranean diet/minddiet (olive oil, nuts) 4. outpatients: hba1c ≥6.5% inpatients: hba1c ≥6.5% or diagnosed diabetes mellitus if hba1c is not available in kisim 5. bmi \> 30 kg/m2 6. individuals per se not willing to change diet 7. instable clinical conditions (e.g. acute infection) at enrolment 8. patients with active cancer (except non-melanoma skin cancer) or current cancer treatment or any other advanced severe disease 9. living in a nursing home and/or receiving prepared meals (i.e. usually not eating home cooked meals) 10. inability to read and or speak german necessary to understand the instructions

Keywords: mediterranean diet mind diet healthy aging
the effect of opioid-free general anesthesia

Conditions: Gynecologic Disease

Summary: this study is performed to investigate the effect of opioid-free general anesthesia on the recovery quality after gynecological laparoscopy.

the quality of recovery after the surgery is assessed using the qor 40. in addition, the various kinds of cytokine are assessed for the ancillary study.

Eligibility criteria:
inclusion criteria: * patient scheduled for gynecological laparoscopic surgery exclusion criteria: 1. refusal to participate in this study 2. emergent surgery 3. chronic pain requiring for pain killer 4. psychiatric disease 5. preoperative bradycardia or hypotension 6. allergy or history of the adverse effect to study drug 7. pregnancy or lactation
ultrafiltration in pediatric cardiac surgery: an observational cohort study

Conditions: Congenital Heart Disease; Inflammation

Summary: infants and children undergoing cardiac surgery with cardiopulmonary bypass (cpb) can experience systemic inflammation that prolongs post-operative recovery. ultrafiltration is an intra-opreative technique that is hypothesized to extract circulating inflammatory mediators during the cpb time. there have been only a few small studies looking at a limited number of inflammatory marker profiles in this context. our institution uses an innovative form of ultrafiltration "subzero-balance simple-modified ultrafiltration" (sbuf-smuf) throughout the entire cpb time. sbuf-smuf has been our standard of care for the last 5 years. this observational seeks to describe the clinical and immunologic outcomes of infants and children undergoing cardiac surgery with cbp and sbuf-smuf.


Eligibility criteria:
inclusion criteria: * congenital cardiac patients (\< 30kg) that have been consented to a planned cardiac surgery procedure requiring cardiopulmonary bypass at the iwk health centre. * patient or family consent to participate in the study. exclusion criteria: * patient or family refusal to participate. * known genetic syndrome with multi-organ abnormalities and immune dysfunction such as digeorge syndrome, trisomy 18 or 13, noonan syndrome. * known immunodeficiency syndrome or bone marrow pathology. * severe liver disease with abnormal synthetic liver function tests.